Co-infection of active pulmonary tuberculosis and invasive pulmonary aspergillosis following a liver transplant: a case report.

Co-infection of active pulmonary tuberculosis and invasive pulmonary aspergillosis following a liver transplant: a case report.

Publication date: Sep 29, 2025

We report a rare case of co-infection involving pulmonary tuberculosis and invasive aspergillosis following a liver transplant. A 25-year-old female housewife immigrant from Afghanistan, who had autoimmune hepatitis and underwent a liver transplant, presented with a history of fever and cough for over a month. Probable diagnosis of pulmonary tuberculosis and invasive aspergillosis was made by chest CT, as evidenced by a positive AFB and aspergillosis smear, and MTB PCR, along with the presence of galactomannan antigen in the BAL fluid. The patient improved after 9 months of treatment with anti-tuberculosis and anti-fungal. In an endemic setting, the probability of pulmonary tuberculosis is elevated, and co-infection with invasive pulmonary aspergillosis, though rare, is significantly more complex. Early detection and targeted management are crucial for improving outcomes.

Open Access PDF

Concepts Keywords
Afghanistan Adult
Hepatitis Antifungal Agents
Housewife Antifungal Agents
Old Antitubercular Agents
Pcr Antitubercular Agents
Case report
Coinfection
Female
galactomannan
Galactose
Galactose
Humans
Invasive Pulmonary Aspergillosis
Invasive pulmonary aspergillosis
Liver transplant
Liver Transplantation
Mannans
Mannans
Pulmonary tuberculosis
Tomography, X-Ray Computed
Tuberculosis, Pulmonary

Semantics

Type Source Name
disease MESH Co-infection
disease MESH pulmonary tuberculosis
disease MESH invasive pulmonary aspergillosis
disease MESH aspergillosis
disease MESH autoimmune hepatitis
disease IDO history
drug DRUGBANK Dimercaprol
disease MESH tuberculosis
pathway KEGG Tuberculosis
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH drug toxicity
disease MESH drug interaction
disease MESH emergency
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH weight loss
drug DRUGBANK Oxygen
drug DRUGBANK Medical air
drug DRUGBANK Prednisolone
drug DRUGBANK Tacrolimus
drug DRUGBANK Mycophenolate mofetil
drug DRUGBANK Monomethyl fumarate
disease IDO blood
disease MESH COVID 19
disease MESH influenza
disease MESH viral load
drug DRUGBANK Riboprine
pathway KEGG Influenza A
drug DRUGBANK Isoniazid
drug DRUGBANK Pyrazinamide
drug DRUGBANK Rifampicin
drug DRUGBANK Itraconazole
drug DRUGBANK Voriconazole
pathway REACTOME Infectious disease
disease IDO infectious disease
disease MESH invasive fungal infections
disease IDO immunosuppression
disease MESH anorexia
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH pulmonary aspergillosis
drug DRUGBANK Everolimus
disease MESH Cancer
disease MESH Mycoses
disease MESH opportunistic infections
drug DRUGBANK Ciclosporin
drug DRUGBANK Rifabutin
drug DRUGBANK Posaconazole
drug DRUGBANK Sirolimus
drug DRUGBANK Ethambutol
drug DRUGBANK Trestolone
disease MESH hemophagocytic lymphohistiocytosis
disease MESH Allergy
drug DRUGBANK Etoperidone
disease MESH sequelae
disease MESH abscess
drug DRUGBANK Rasagiline
drug DRUGBANK Galactose

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *